1 – 10 of 87
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
(
- Contribution to journal › Article
-
Mark
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
(
- Contribution to journal › Article
-
Mark
Prediction of lymph node metastasis in breast cancer by gene expression and clinicopathological models: Development and validation within a population based cohort.
(
- Contribution to journal › Article
-
Mark
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
(
- Contribution to journal › Article
-
Mark
Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations : effect of a prospective intervention in primary bladder cancer patients
(
- Contribution to journal › Article
-
Mark
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)
(
- Contribution to journal › Article
-
Mark
Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence
(
- Contribution to journal › Article
-
Mark
Artificial neural network models to predict nodal status in clinically node-negative breast cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
-
Mark
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer : The RASTEN trial
(
- Contribution to journal › Article